Lung Cancer on Dual Brain Lab

SCLC Clinical Trial Timeline: A 25-Year Dual-Track Map

Tue, 21 Apr 2026 00:00:00 +0000

SCLC Clinical Trial Timeline: In-Depth Research Report

Coverage: 30 landmark trials cited by NCCN Small Cell Lung Cancer V1.2026 (28 published with full PMID traceability + 2 design/protocol papers with primary results pending) + two stages (LS-SCLC limited-stage / ES-SCLC extensive-stage) + five paradigms (concurrent chemoradiation / 1L chemoimmunotherapy / PCI / 2L and later lines / maintenance exploration)

Curated by Dual Brain Lab (csilab.net)

1. One-Sentence Definition

This report maps the evolution logic and current decision landscape of landmark clinical trials for systemic treatment of small cell lung cancer (SCLC) cited by NCCN Small Cell Lung Cancer V1.2026 over the past 27 years (1999-2026), providing frontline clinicians in 2026 a traceable panoramic map for “who, what, and why” decisions.

Iron rule: every data point in every trial is traceable to PubMed (PMID) or ClinicalTrials.gov (NCT id) — each [PMID xxxxxxxx] in the text can be directly opened for PubMed source verification.

2. Longitudinal: Evolution Timeline of Five Treatment Paradigms

SCLC systemic treatment has undergone five paradigm shifts over 27 years: LS-SCLC (limited-stage) concurrent chemoradiation established by Turrisi 1999 hyperfractionated acceleration → ES-SCLC (extensive-stage) etoposide + platinum (EP) backbone and 2L topotecan 20-year plateau → thoracic radiotherapy + PCI (prophylactic cranial irradiation) filled the brain-protection gap during 2007-2015 → 2018 IMpower133 and 2019 CASPIAN broke the 20-year OS (overall survival) ceiling using PD-(L)1 inhibitor class effect → 2024 ADRIATIC upgraded LS-SCLC to cCRT (concurrent chemoradiation) + durvalumab consolidation as the new standard, while in the same year DeLLphi-301 opened SCLC’s first truly non-chemotherapy new mechanism in half a century using tarlatamab (DLL3 × CD3 BiTE, bispecific T-cell engager).

Each shift has been smaller in magnitude than in NSCLC — reflecting SCLC’s unique biology: no unified driver mutation + neuroendocrine differentiation + MYC / ASCL1 / NEUROD1 / POU2F3 / YAP1 molecular subtype heterogeneity + rapid chemoresistance + low tumor mutation burden (TMB) → the NSCLC “EGFR/ALK/KRAS ten-gene + IO backbone” model does not apply to SCLC. SCLC’s paradigm evolution follows a three-stage arc: “20-year chemotherapy plateau + IO marginal victory + DLL3 BiTE breakthrough.”

2.1 LS-SCLC Concurrent Chemoradiation Foundations (1999-2024): BID acceleration → QD non-inferiority → SIB dose escalation

Story: in 1999 TURRISI INT-0096 pushed LS-SCLC radiotherapy from QD (once daily) 5 weeks to BID (twice daily) 3 weeks 45 Gy hyperfractionated acceleration, raising 2-year OS from 41% to 47%. But BID had poor clinical feasibility (twice-daily outpatient radiotherapy + esophagitis), so for 18 years Europe and North America wanted to return to QD but lacked evidence, until CONVERT proved 66 Gy QD non-inferior, validating the “more convenient dose” approach, and CALGB-30610 used 70 Gy QD to confirm numerical closeness. In 2024 Yu et al used SIB (simultaneous integrated boost) 54 Gy BID to push mOS to 60.7 months — the first time a Chinese cohort raised the radiotherapy dose further.

INT-0096 (TURRISI 1999) [PMID 9920950] (Turrisi 1999 NEJM): LS-SCLC 45 Gy BID 3 weeks vs 45 Gy QD 5 weeks + cisplatin/etoposide. mOS 23 vs 19 months (p=0.04), 2-year OS 47% vs 41%, 5-year OS 26% vs 16%. Grade 3 esophagitis 32% vs 16%. Established “LS-SCLC cCRT + BID 45 Gy” as North American SoC (standard of care) for 25 years.
CONVERT [PMID 28642008] (Faivre-Finn 2017 Lancet Oncol): LS-SCLC 66 Gy QD 6.5 weeks vs 45 Gy BID 3 weeks + cisplatin/etoposide. mOS 30 months (BID) vs 25 months (QD), HR 1.18 (95% CI 0.95-1.45, p=0.14) — non-inferiority achieved, toxicity profiles similar. Europe and North America finally had evidence that “QD is non-inferior to BID,” and clinical practice shifted back to QD.
CALGB 30610 / RTOG 0538 [PMID 36623230] (Bogart 2023 JCO): LS-SCLC 70 Gy QD vs 45 Gy BID + platinum-etoposide. mOS 30.1 vs 28.5 months, HR 0.94 (95% CI 0.76-1.17). 70 Gy QD confirmatory in North America, aligned with CONVERT — high-dose QD = standard-dose BID.
YU-2024-HYPERFRAC [PMID 39146944] (Yu 2024 Lancet Respir Med): LS-SCLC VMAT 54 Gy SIB BID 30 fractions vs 45 Gy BID 30 fractions. mOS 60.7 vs 39.5 months, HR 0.55 (95% CI 0.37-0.72, p=0.003) — adding 9 Gy gained 21 months of OS. Grade 3-4 esophagitis 11% vs 4%. Bold Chinese single-center design, awaiting Western confirmatory trials.
ADRIATIC [PMID 39268857] (Cheng 2024 NEJM): LS-SCLC post-cCRT non-progressors, durvalumab 1500 mg q4w consolidation for up to 24 months vs placebo. mOS 55.9 vs 33.4 months, HR 0.73 (98.321% CI 0.54-0.98, p=0.01), mPFS 16.6 vs 9.2 months. First time in 30 years that post-cCRT OS was significantly extended in LS-SCLC — the SCLC version of PACIFIC’s playbook for stage III NSCLC moving from cCRT observation to durvalumab consolidation.
NRG LU005 [PMID 41529214] (Higgins 2026 JCO): LS-SCLC cCRT (66 Gy QD or 45 Gy BID) + atezolizumab concurrent + adjuvant 17 cycles vs cCRT alone. mOS 31.1 vs 36.1 months, HR 1.03 (95% CI 0.80-1.32) negative. “Concurrent IO + cCRT” failed in LS-SCLC — “sequential durvalumab consolidation” (ADRIATIC) is the correct path.

Takeaway: in 2026, LS-SCLC SoC = cCRT (either BID 45 Gy or QD 66-70 Gy) → durvalumab consolidation up to 24 months (ADRIATIC). The “concurrent IO + cCRT” path (NRG LU005) has been refuted. Yu 2024’s 54 Gy SIB dose escalation is a Chinese single-center exploratory signal awaiting larger confirmatory trials.

2.2 ES-SCLC 1L Chemotherapy Plateau (1999-2019): EP backbone 20 years + topotecan vs CAV anchoring 2L

Story: before the IO era, 1L standard for ES-SCLC was EP (etoposide + platinum) 4-6 cycles with an mOS ceiling of 9-10 months. All attempts to add a third drug (paclitaxel / lobaplatin substitution) failed and only doubled toxicity. 2L topotecan, after a 1999 phase III vs CAV (cyclophosphamide + doxorubicin + vincristine) proved single-agent non-inferiority + better quality of life, sat firmly as the 2L standard until tarlatamab arrived in 2024.

TOPOTECAN-ORIGINAL-PHASE2 [PMID 10080612] (von Pawel 1999 JCO): relapsed SCLC topotecan 1.5 mg/m² d1-5 q21d vs CAV. ORR 24.3% vs 18.3% (p=0.285), mTTP (time to progression) 13.3 vs 12.3 weeks (p=0.552), mOS numerically close. Single-agent topotecan non-inferior to three-drug CAV + better symptom improvement — established topotecan as SCLC 2L standard for 20+ years.
NIELL-2002-INTERGROUP [PMID 15923572] (Niell 2005 JCO): ES-SCLC 1L paclitaxel + EP + G-CSF vs EP × 6 cycles. mOS 10.6 vs 9.9 months, p=0.169 negative, G3-4 toxicity increased. “Add a taxane to EP” approach refuted — EP is the ES-SCLC 1L chemotherapy ceiling.
OBRIEN-TOPOTECAN-2006 [PMID 17135646] (O’Brien 2006 JCO): relapsed SCLC oral topotecan 2.3 mg/m² d1-5 q21d + BSC (best supportive care) vs BSC alone. mOS 25.9 vs 13.9 weeks (log-rank p=0.0104), ORR 7% PR + 44% DCR. Oral topotecan vs BSC established that “even when no new drug is available, 2L topotecan beats BSC” — the minimum-care baseline for SCLC 2L.
EL-PHASE3-CHINA [PMID 30988825] (Cheng 2019 Oncol Lett): ES-SCLC 1L lobaplatin + etoposide (EL) vs cisplatin + etoposide (EP). mPFS 5.1 vs 5.3 months (p=0.786), mOS 10.6 vs 9.7 months (p=0.701). Chinese non-inferiority demonstrated lobaplatin vs cisplatin equivalence in ES-SCLC 1L, providing a platinum alternative for patients intolerant to nephrotoxicity / vomiting — the last “chemotherapy optimization” before the IO era.

Takeaway: across these 20 years (1999-2019), ES-SCLC 1L ceiling held steady at mOS 9-10 months, 2L topotecan single-agent at ~25 weeks — two “plateau” numbers defined what IO had to break. All attempts to add a third chemo drug / substitute the platinum failed.

2.3 ES-SCLC Thoracic RT + PCI Brain Protection (2007-2021): add RT + PCI → dose + fraction optimization

Story: before 2007, ES-SCLC post-chemo responders went straight to observation. Slotman 2007 proved PCI 25 Gy after chemo response substantially reduced brain metastases and extended OS; CREST 2014 proved thoracic RT 30 Gy/10 fx also delivered 2-year OS benefit. From 2009-2021 three trials (PCI99-01 dose optimization + RTOG-0212 hippocampal avoidance) refined PCI to “low dose + cognitive protection.”

SLOTMAN-PCI-2007 [PMID 17699816] (Slotman 2007 NEJM): ES-SCLC post-chemo response PCI 25 Gy vs observation. 1-year symptomatic brain metastasis risk 14.6% vs 40.4% (HR 0.27, 95% CI 0.16-0.44, p<0.001), 1-year OS 27.1% vs 13.3% (HR 0.68, 95% CI 0.52-0.88, p=0.003). Pivotal evidence establishing ES-SCLC PCI as SoC, widely adopted globally after 2007.
PCI99-01 [PMID 19386548] (Le Péchoux 2009 Lancet Oncol): LS-SCLC cCRT CR (complete response) PCI 36 Gy vs 25 Gy dose comparison. 2-year brain metastases 23% vs 29% (36 Gy vs 25 Gy), HR 0.80 (95% CI 0.57-1.11) negative; 36 Gy arm had more chronic neurotoxicity. 25 Gy low dose non-inferior + less toxicity — LS-SCLC PCI standard dose locked at 25 Gy.
CREST (SLOTMAN-2015) [PMID 25230595] (Slotman 2015 Lancet): ES-SCLC post-chemo response thoracic RT 30 Gy/10 fx + PCI vs PCI alone. 1-year OS 33% vs 28% (HR 0.84, 95% CI 0.69-1.01, p=0.066 not significant), 2-year OS 13% vs 3% (p=0.004 significant). “Long-tail OS benefit” — a subset of patients indeed benefits from thoracic RT, but not significant at the 1-year landmark. NCCN retains as an optional option.
RTOG-0212-HIPPO (Belderbos 2021) [PMID 33545387] (Belderbos 2021 JTO): SCLC post-chemo PCI 25 Gy standard whole-brain vs HA-PCI (hippocampal-avoidance PCI) 25 Gy. 4-month HVLT-R total recall decline ≥5 points: 29% vs 28% (p=1.000) — HA-PCI did not show clear cognitive protection advantage in this study, inconsistent with earlier small-scale NRG CC001 data. Guideline wording retains HA-PCI as optional but evidence is not coherent.

Takeaway: 2026 PCI decisions — LS-SCLC cCRT CR then PCI 25 Gy (PCI99-01 dose-locked) remains SoC; ES-SCLC post-chemo response PCI 25 Gy based on Slotman 2007 but in the IO era some European centers substitute brain MRI surveillance (lacks head-to-head RCT); CREST thoracic RT kept as an option (strong 2-year OS signal but 1-year OS not significant); HA-PCI evidence is inconsistent (RTOG-0212 negative).

2.4 ES-SCLC 1L IO Breakthrough (2018-2025): class-effect marginal victory + Chinese PD-1 catch-up

Story: in 2018 IMpower133 used atezolizumab + chemo to push ES-SCLC’s 20-year ceiling from mOS 10 months to 12.3 months, HR 0.70 — the first positive phase III for IO in SCLC 1L. In 2019 CASPIAN reproduced the same path with durvalumab, HR 0.73. Two independent phase IIIs converging in the narrow HR 0.70-0.73 band = textbook definition of class effect. From 2022-2025, five domestic Chinese phase IIIs (ASTRUM-005 serplulimab / CAPSTONE-1 adebrelimab / RATIONALE-312 tislelizumab / EXTENTORCH toripalimab / ETER701 benmelstobart + anlotinib) propelled ES-SCLC 1L into a “Chinese PD-1/PD-L1 flourishing” era, with Chinese regimens’ mOS numerically higher than IMpower133/CASPIAN (15-19 months vs 12-13 months), though cross-trial population differences require cautious interpretation.

IMPOWER133 [PMID 30280641] (Horn 2018 NEJM): ES-SCLC treatment-naïve atezolizumab + carboplatin + etoposide vs placebo + carboplatin + etoposide. mOS 12.3 vs 10.3 months (HR 0.70, 95% CI 0.54-0.91, p=0.007), mPFS 5.2 vs 4.3 months (HR 0.77, p=0.02). First OS-positive phase III in SCLC in 20 years. FDA approved 2019-03.
IMBRELLA-A (IMpower133 5y) [PMID 39306923] (Reck 2024 Lung Cancer): IMpower133 ITT 5-year long-term follow-up extension. 3/4/5-year OS atezolizumab arm 16%/13%/12% — “long-tail survivor” confirmed, about 12% of patients alive at 5 years (historical chemo-alone 3-4%). IO benefit concentrated in a “durable responder” subgroup, not uniformly lifting the entire population.
CASPIAN [PMID 31590988] (Paz-Ares 2019 Lancet): ES-SCLC treatment-naïve durvalumab + platinum-etoposide (EP/EC) vs EP/EC. mOS 13.0 vs 10.3 months (HR 0.73, 95% CI 0.59-0.91, p=0.0047). Global regimen + durvalumab maintenance through progression (rather than stopping at 4-6 cycles). FDA approved 2020-03, HR converging with IMpower133 in the 0.70-0.73 band — establishing IO + platinum/etoposide class effect.
ASTRUM-005 [PMID 36166026] (Cheng 2022 JAMA): ES-SCLC treatment-naïve serplulimab (HLX10 PD-1) + carboplatin + etoposide vs placebo + carboplatin + etoposide. mOS 15.4 vs 10.9 months (HR 0.63, 95% CI 0.49-0.82, p<0.001), 24-month OS rate 43.1% vs 7.9%. First Chinese PD-1 to post OS HR 0.63 in ES-SCLC 1L — numerically higher than IMpower133/CASPIAN, population predominantly Asian.
CAPSTONE-1 [PMID 35576956] (Wang 2022 Lancet Oncol): ES-SCLC treatment-naïve adebrelimab (SHR-1316 PD-L1) + carboplatin + etoposide vs placebo + carboplatin + etoposide. mOS 15.3 vs 12.8 months (HR 0.72, 95% CI 0.58-0.90). Chinese PD-L1 version of IMpower133 repeat, HR close to CASPIAN.
RATIONALE-312 [PMID 38460751] (Cheng 2024 JTO): ES-SCLC treatment-naïve tislelizumab (PD-1) + etoposide + carboplatin/cisplatin vs placebo + etoposide + carboplatin/cisplatin. mOS 15.5 vs 13.5 months (HR 0.75, 95% CI 0.61-0.93, one-sided p=0.0040). The third Chinese IO confirming class effect.
EXTENTORCH [PMID 39541202] (Cheng 2025 JAMA Oncol): ES-SCLC treatment-naïve toripalimab (PD-1) + EP vs placebo + EP. mOS 14.6 vs 13.3 months (HR 0.80, 95% CI 0.65-0.98, p=0.03), PFS HR 0.67. The fourth Chinese IO added to EP.
ETER701 [PMID 38992123] (Cheng 2024 Nat Med): ES-SCLC treatment-naïve benmelstobart (PD-L1) + anlotinib (multi-target TKI) + etoposide + carboplatin four-drug regimen vs dual placebo + etoposide + carboplatin. Four-drug arm mOS 19.3 vs 11.9 months (HR 0.61, p=0.0002); anlotinib + EC (three-drug arm) also superior to EC. Highest mOS record in ES-SCLC 1L history; G3+ TRAE 93.1% approaching universal. “Adding anti-angiogenic TKI to IO + chemo” is the new intensification direction for ES-SCLC 1L, but at a high toxicity cost.

Takeaway: in 2026, ES-SCLC 1L SoC = IO + platinum/etoposide × 4-6 cycles → IO maintenance (atezolizumab / durvalumab / serplulimab / adebrelimab / tislelizumab / toripalimab, any one; class effect HR 0.63-0.80 narrow band). ETER701 four-drug regimen mOS 19.3 months is the Chinese exploration peak but toxicity cost is high; choice depends on clinical tradeoff. The “long-tail 12% 5-year survival” is the most critical structural change in the IO era for ES-SCLC — not raising everyone’s OS by 2-3 months, but giving 12% of “durable responders” a 5-year+ survival window.

2.5 ES-SCLC 2L+ and Maintenance Exploration (2016-2026): tarlatamab DLL3 BiTE breakthrough + IO monotherapy failure + flourishing maintenance combinations

Story: IO monotherapy was initially given high hopes in SCLC 2L+; CheckMate-032 nivolumab ± ipilimumab and KEYNOTE-028/158 pembrolizumab both showed ORR 10-22% signals, but without phase III level OS evidence, FDA successively withdrew these two SCLC indications during 2018-2020 — IO monotherapy in unselected 2L populations is not practice-changing. Until 2023, when DeLLphi-301 used tarlatamab (DLL3 × CD3 BiTE) in 2L+ to achieve cORR 40%, mDoR (median duration of response) 6.9 months, and FDA accelerated approval 2024-05, marking the first time in half a century SCLC had a “non-chemotherapy new mechanism” receive regulatory approval. From 2024-2026 maintenance/combination explorations (DeLLphi-303 / DURABLE / TREASURE / MATCH) rolled out densely, exploring four combination directions: “IO + tarlatamab / IO + anti-angiogenic / IO + thoracic RT / IO + low-dose RT.” TRACES used trilaciclib to reposition myeloprotection as an SCLC chemotherapy adjunct.

CHECKMATE-032 [PMID 27269741] (Antonia 2016 Lancet Oncol): relapsed SCLC nivolumab monotherapy or nivolumab + ipilimumab various doses. ORR: nivo3 10% (10/98), nivo1+ipi3 23% (14/61), nivo3+ipi1 19% (10/54); durable response signal but small sample, no control. FDA 2018-08 accelerated approval for nivolumab SCLC 3L based on this basket data, but withdrawn 2020-12 (CheckMate-331/451 confirmatory failed).
KEYNOTE-028-158 [PMID 31870883] (Chung 2020 JTO): relapsed SCLC ≥2L pembrolizumab monotherapy pooled analysis. ORR 19.3% (95% CI 11.4-29.4), 2 CR + 14 PR, 61% of responders DoR ≥18 months. FDA 2019-06 accelerated approval for pembrolizumab SCLC 3L, withdrawn 2021-03 (KEYNOTE-604 1L confirmatory negative). IO monotherapy in unselected 2L+ SCLC showed seemingly decent ORR but no phase III OS support — what regulators ultimately required.
DELLPHI-301 [PMID 37861218] (Ahn 2023 NEJM): previously treated SCLC 2L+ tarlatamab 10 mg or 100 mg IV every 2 weeks. ORR 40% (10 mg arm, cORR 40% per BICR) vs 32% (100 mg), mPFS 4.9 vs 3.9 months, 9-month OS 68% (10 mg arm), mDoR 6.9 months. Severe CRS (cytokine release syndrome) 1%, low-grade CRS ~50% mostly at first dose, managed via step-up dosing. First non-chemotherapy non-IO new mechanism in SCLC in half a century — FDA accelerated approval 2024-05.
DELLPHI-303 [PMID 40934933] (Paulson 2025 Lancet Oncol): ES-SCLC 1L post-chemoimmunotherapy tarlatamab + atezolizumab or durvalumab maintenance. From maintenance start mOS 25.3 months (95% CI 20.3-NE), severe CRS 24% — safety signal in 1L maintenance setting is manageable. Phase III NCT06211036 ongoing, expected to push tarlatamab from 2L+ to 1L maintenance.
DURABLE [PMID 37947242] (Zhang 2023 Clin Respir J, protocol paper): ES-SCLC 1L post-chemo response durvalumab + anlotinib maintenance vs durvalumab maintenance. Only protocol published, primary efficacy results not yet PubMed-indexed (conference reports PFS 9.0 vs 5.6 months) — representative of “anti-angiogenic + IO combination maintenance” direction.
TREASURE [PMID 36153496] (Bozorgmehr 2022 BMC Cancer, protocol paper): ES-SCLC 1L post-response atezolizumab + thoracic RT (TRT) vs atezolizumab maintenance alone. Protocol design stage; trial terminated due to toxicity. CREST thoracic RT + IO maintenance verification attempt failed.
MATCH-TRIAL-SCLC [PMID 40609842] (Zhou 2026 Int J Radiat Oncol Biol Phys): ES-SCLC 1L cisplatin/carboplatin + etoposide + atezolizumab + concurrent low-dose RT (LDRT, 15 Gy/5 fx). Confirmed ORR 87.5% (95% CI 75.9-94.8), mPFS 6.9 months (95% CI 5.4-9.3) — single-arm phase II, early signal for “LDRT + IO + chemo” in ES-SCLC 1L, ORR far higher than IMpower133/CASPIAN. Awaiting phase III validation.
TRACES [PMID 38224653] (Cheng 2024 Lung Cancer): ES-SCLC chemotherapy trilaciclib (CDK4/6 inhibitor myeloprotection) pre-dosed vs placebo + etoposide + carboplatin. Cycle 1 DSN (duration of severe neutropenia) 0 vs 2 days (p=0.0003), mOS 12.0 vs 8.8 months (HR 0.69, 95% CI ). Trilaciclib already FDA-approved in the US 2021 — turning chemotherapy myelosuppression from “unavoidable side effect” into “pharmacologically preventable.”

Takeaway: in 2026, SCLC 2L+ SoC = tarlatamab (DeLLphi-301, FDA 2024-05 accelerated) is the preferred non-chemotherapy new mechanism; single-agent topotecan or lurbinectedin (FDA 2020 accelerated, not in this yaml) as non-BiTE alternatives; IO monotherapy (nivolumab / pembrolizumab) SCLC indications withdrawn, limited to tumor-agnostic MSI-H / TMB-H. The four maintenance/combination directions (tarlatamab maintenance / anti-angiogenic maintenance / thoracic RT + IO / LDRT + IO) are the most active battlegrounds for 2026-2028.

3. Horizontal: 2026 Current Decision Landscape (Six Dimensions)

Projecting longitudinal evolution onto 2026’s concrete clinical decision tree, the following are six key branchpoints and the evidence underpinning each.

3.1 LS-SCLC Initial Treatment: cCRT + durvalumab consolidation, new standard

2026 mainstream: curative-intent LS-SCLC fit patients = cCRT (cisplatin/etoposide × 4-6 cycles + thoracic RT 45 Gy BID / 3 weeks or 66-70 Gy QD / 6-7 weeks) → post-cCRT non-progressors durvalumab 1500 mg q4w consolidation up to 24 months → CR patients PCI 25 Gy or brain MRI surveillance.

Key branchpoints:

Subgroup	First choice	Alternative
fit LS-SCLC standard risk	cCRT (45 Gy BID / 66 Gy QD) → durvalumab consolidation (ADRIATIC) → PCI 25 Gy [TURRISI PMID 9920950 / CONVERT PMID 28642008 / ADRIATIC PMID 39268857 / PCI99-01 PMID 19386548]	70 Gy QD [CALGB 30610 PMID 36623230]
fit LS-SCLC Chinese center (exploratory)	54 Gy SIB BID [YU-2024 PMID 39146944] → durvalumab consolidation	Return to 45 Gy BID + ADRIATIC consolidation
IO intolerant / active autoimmunity	cCRT standard dose + observation (no durvalumab consolidation)
Elderly / PS 2 LS-SCLC	Sequential chemoradiation (SeqCRT) instead of cCRT, toxicity de-escalation
cCRT failure / progression	2L per ES-SCLC 2L+ decision

Not recommended in 2026: concurrent atezolizumab + cCRT — NRG LU005 (PMID 41529214) HR 1.03 negative + OS numerically lower (31.1 vs 36.1 months); “concurrent IO + cCRT” in LS-SCLC does not replicate the PACIFIC stage III NSCLC script.

3.2 ES-SCLC 1L: IO + platinum/etoposide class effect + Chinese PD-1 accessibility branch

2026 mainstream: ES-SCLC fit treatment-naïve = IO (PD-(L)1 inhibitor, 6-7 choices) + carboplatin or cisplatin + etoposide × 4-6 cycles → IO maintenance until progression or intolerance.

Key branchpoints:

Subgroup	First choice	Alternative
fit global / Western	atezolizumab + carboplatin + etoposide [IMpower133 PMID 30280641 + 5y PMID 39306923] or durvalumab + EP/EC [CASPIAN PMID 31590988]	EP/EC alone (IO intolerant)
fit China / Asia	serplulimab + carboplatin + etoposide [ASTRUM-005 PMID 36166026] or adebrelimab + carboplatin + etoposide [CAPSTONE-1 PMID 35576956] or tislelizumab + EP/EC [RATIONALE-312 PMID 38460751] or toripalimab + EP [EXTENTORCH PMID 39541202]	atezolizumab / durvalumab (when accessible)
fit, seeking highest OS + willing to tolerate ~93% G3+ toxicity	benmelstobart + anlotinib + EC four-drug [ETER701 PMID 38992123]	Three-drug IO + platinum/etoposide
ECOG 2 / heavy comorbidities / elderly	IO + carboplatin + etoposide (avoid cisplatin), strengthen BSC	EP alone
Nephrotoxicity, cisplatin intolerant	lobaplatin + etoposide [EL-PHASE3-CHINA PMID 30988825] ± IO	carboplatin + etoposide
High risk of severe myelosuppression	Consider trilaciclib myeloprotection pre-dosing [TRACES PMID 38224653]	Dose reduction

Clinical meaning of “long-tail survivor”: IMBRELLA-A 5y OS 12% (PMID 39306923) tells us — ES-SCLC IO + chemo benefit is not uniformly lifting everyone 2-3 months, but giving about 12% of “durable responders” a 5-year+ survival window. When communicating prognosis, clinicians should clearly distinguish the dual-layer structure of “median OS 13-15 months (majority) + 5-year OS 12% (long tail).”

NCCN 2026: IO + platinum/etoposide = Category 1 preferred (atezolizumab / durvalumab globally; serplulimab / adebrelimab / tislelizumab / toripalimab in China based on CSCO 2025).

3.3 PCI Decision: Is PCI Still Needed in the IO Era?

2026 mainstream:

LS-SCLC cCRT + durvalumab consolidation CR patients: PCI 25 Gy remains SoC (PCI99-01 PMID 19386548 dose-locked); some centers switch to brain MRI q3-6 month surveillance as a PCI substitute (lacks head-to-head RCT)
ES-SCLC chemo + IO responders: Slotman 2007 (PMID 17699816) PCI 25 Gy remains standard evidence → but in the IO era (IMpower133 / CASPIAN both protocol-permitted PCI by investigator choice), actual usage has declined; brain MRI surveillance is the European alternative in some centers
HA-PCI (hippocampal-avoidance): RTOG-0212 PMID 33545387 did not show clear cognitive protection advantage, inconsistent with earlier small-scale data; NCCN retains as optional but not strongly recommended
Thoracic RT (TRT): CREST PMID 25230595 2-year OS 13% vs 3% significant + 1-year not significant — whether to add TRT in the IO era is in guideline “optional” status; TREASURE PMID 36153496 “IO + TRT” terminated due to toxicity suggests risk

Key controversy: is PCI still needed in the IO era? — this is the most divisive clinical question in SCLC 2026. No IO vs PCI head-to-head RCT; some European centers have already substituted MRI for PCI; Asian / North American majority still retain PCI. MAVERICK / PRIMALung phase III RCTs are enrolling but no readout as of 2026-04.

3.4 ES-SCLC 2L+: tarlatamab preferred + topotecan alternative + IO monotherapy not used

2026 mainstream:

Subgroup	First choice	Alternative
DLL3+ SCLC post-1L IO + chemo progression	tarlatamab 10 mg IV q2w [DeLLphi-301 PMID 37861218]	IV or oral topotecan
DLL3 not tested / not enriched	Oral topotecan [OBRIEN-TOPOTECAN-2006 PMID 17135646 vs BSC]	IV topotecan / lurbinectedin (FDA 2020 accelerated)
Prior good IO response + tarlatamab CRS intolerant	Rechallenge IO + chemo (if interval > 6 months)	Clinical trial
MSI-H / dMMR / TMB-H rare SCLC subgroup	pembrolizumab tumor-agnostic	nivolumab tumor-agnostic
3L+ standard exhausted	Clinical trial > regorafenib / ADC / CAR-T exploration	BSC

Not recommended in 2026:

nivolumab or pembrolizumab monotherapy in unselected SCLC 2L+ — CheckMate-032 (PMID 27269741) and KEYNOTE-028/158 (PMID 31870883) SCLC accelerated approvals were withdrawn by FDA 2020-12 / 2021-03 respectively. Only tumor-agnostic MSI-H / TMB-H subgroups retain IO monotherapy use.
CAV three-drug — single-agent topotecan is non-inferior (PMID 10080612) + single-agent more convenient + lower toxicity.

3.5 Maintenance / Combination Exploration: Four Directions Flourishing

2026 mainstream: ES-SCLC 1L IO + chemo × 4-6 cycles → IO maintenance until progression. On this foundation, four “IO maintenance intensification” directions are being explored:

Direction	Representative trial	2026 clinical status
tarlatamab maintenance (DLL3 BiTE + IO)	DeLLphi-303 [PMID 40934933] + phase III NCT06211036	Phase II 25.3-month mOS signal strong; phase III ongoing
anti-angiogenic + IO maintenance	DURABLE [PMID 37947242] durvalumab + anlotinib maintenance vs durvalumab	Protocol-only, awaiting primary readout; conference-reported PFS signal
Thoracic RT (TRT) + IO maintenance	TREASURE [PMID 36153496] (terminated due to toxicity)	TRT + IO maintenance approach failed; CREST-era TRT retained as standalone
Low-dose RT (LDRT) + IO + chemo concurrent	MATCH-TRIAL-SCLC [PMID 40609842]	Phase II ORR 87.5% signal strong, awaiting phase III validation

Clinical implication: these four directions represent “how much more benefit can be squeezed from ES-SCLC 1L maintenance” — DeLLphi-303 is most likely to rewrite 1L maintenance standard in 2026-2028 (phase III NCT06211036); MATCH LDRT + IO may reopen thoracic RT’s IO-era value; anti-angiogenic maintenance may be replaced by ETER701’s four-drug 1L regimen, eliminating the need for sequential “maintenance + anti-angio.”

3.6 Elderly / Poor PS SCLC + Transformed SCLC Subgroups

Elderly (≥75 years) / PS 2 ES-SCLC: IMpower133 / CASPIAN / ASTRUM-005 and other IO + chemo phase IIIs predominantly enrolled PS 0-1 (PS 2 <10%). Clinical decisions:

PS 2 but chemo-tolerant: dose-reduced IO + carboplatin (avoid cisplatin) + etoposide + trilaciclib myeloprotection (TRACES PMID 38224653)
PS 3-4 / multi-organ failure: BSC + palliative RT (symptomatic brain metastases / bone metastases)
85+ ES-SCLC: single-agent etoposide or single-agent IO (no dedicated RCT)

Transformed SCLC (EGFR TKI-resistant NSCLC transformed to SCLC): rare subgroup (about 3-10% of EGFR-mutated NSCLC post-osimertinib transforms to SCLC). No prospective RCT; clinical experience is to use SCLC-like chemo (EP/EC) + consider continuing osimertinib (to protect residual NSCLC clones). DeLLphi-301 and other tarlatamab trials typically exclude transformed SCLC — this subgroup has limited 2L+ treatment options, prioritize clinical trial enrollment.

4. Research Gaps: Top Ten Unresolved Clinical Questions

This report identifies the following gaps, all definable specific questions (not platitudes of “more research needed”):

“Within-group differences” across IMpower133 / CASPIAN / Chinese PD-1 series remain unresolved: HR 0.70-0.80 narrow-band convergence = class effect, but IMBRELLA-A 5y OS 12% means 88% of patients still progress rapidly — who is the long-tail responder? Lacks pre-specified PD-L1 / TMB / ASCL1 / dMMR / IFN-γ signature prospective validation.
PCI in the IO era vs MRI surveillance head-to-head missing: PCI standards established by Slotman 2007 and PCI99-01 have not been updated for the IO era; MAVERICK / PRIMALung phase III ongoing but no readout as of 2026-04 — East-West practice divergence (European MRI substitution / Asian-North American PCI retention) lacks evidence-based resolution.
LS-SCLC cCRT sequencing (concurrent vs sequential) contemporary data missing: TURRISI 1999 + CONVERT 2017 + CALGB 30610 2023 are all concurrent RT; sequential chemo + RT only as PS 2 alternative, no IO-era (post-ADRIATIC) concurrent vs sequential head-to-head data.
DLL3 biomarker cutoff not standardized: DeLLphi-301 enrolled DLL3 IHC ≥50% as marker, but is tarlatamab response cORR 40% limited to high expressors? Does any DLL3 expression also have activity? DLL3 IHC assay inter-laboratory variability + cutoff choice = key gap for future SCLC basket trials.
Transformed SCLC (EGFR TKI-resistant transformation) 1L/2L regimens lack prospective data: about 3-10% of NSCLC post-osimertinib transforms to SCLC; clinical decisions are entirely empirical. DeLLphi-301 and other tarlatamab trials exclude this subgroup; transformed SCLC-specific prospective cohort missing.
Clinical actionability of SCLC molecular subtypes (ASCL1 / NEUROD1 / POU2F3 / YAP1): since 2018 Rudin et al defined 4 molecular subtypes; POU2F3 high expression may correlate with lurbinectedin response, YAP1 with IO primary resistance — but no prospective stratified trial readout as of 2026-04, subtyping not routinely applied clinically.
Elderly / PS 2 ES-SCLC IO data sparse: IMpower133 / CASPIAN dominated by PS 0-1, PS 2 subgroup <10%; dedicated elderly / PS 2 SCLC IO RCT missing — clinical decisions based on post-hoc subgroup analyses rather than prespecified.
SCLC CNS progression local (SRS / WBRT) vs systemic (tarlatamab CNS activity) decision not standardized: tarlatamab CNS penetration data limited; IO + chemo CNS ORR not separately reported. Optimal sequencing of SRS + systemic therapy lacks RCT.
Post-2L+ 3L+ options (post-tarlatamab resistance): tarlatamab 2L response 6.9-month mDoR post-resistance has no standard; lacks tarlatamab resistance molecular mechanism characterization + 3L+ ADC / CAR-T / rechallenge chemo data.
Chinese PD-1 class effect internal differences (ASTRUM-005 HR 0.63 vs EXTENTORCH HR 0.80): HR spans 0.63-0.80 (18 percentage points) — is this a true difference or cross-trial population / control / follow-up duration difference? Lacks Chinese PD-(L)1 head-to-head RCT.

5. 2024-2026 Latest Developments

5.1 FDA / NMPA New Approvals and Guideline Expansions

2024-05-16 FDA accelerated approval: tarlatamab (Imdelltra) DLL3 × CD3 BiTE for SCLC 2L+ post-platinum chemo progression / DeLLphi-301 [PMID 37861218] — first non-chemotherapy non-IO new mechanism in SCLC in half a century
2024-08-05 FDA approval: durvalumab (Imfinzi) consolidation for LS-SCLC post-cCRT non-progressors / ADRIATIC [PMID 39268857] — first OS-positive phase III in LS-SCLC in 30 years changing SoC
2022-03 NMPA approval + 2024 global follow-up: adebrelimab (SHR-1316) + EC for ES-SCLC 1L / CAPSTONE-1 [PMID 35576956]
2022-10 NMPA approval: serplulimab (HLX10) + EC for ES-SCLC 1L / ASTRUM-005 [PMID 36166026]
2024 NMPA expanded approval: tislelizumab / toripalimab + EP/EC for ES-SCLC 1L / RATIONALE-312 [PMID 38460751] + EXTENTORCH [PMID 39541202]
2024-01 NMPA approval: benmelstobart + anlotinib + EC four-drug regimen for ES-SCLC 1L / ETER701 [PMID 38992123]
2021-02 FDA approval + 2024 China follow-up: trilaciclib (Cosela) myeloprotection for ES-SCLC chemotherapy / TRACES [PMID 38224653]

2020-12 / 2021-03 FDA withdrawals: nivolumab (CheckMate-032 PMID 27269741) and pembrolizumab (KEYNOTE-028/158 PMID 31870883) SCLC 3L monotherapy indications withdrawn due to confirmatory phase III failures — SCLC IO monotherapy 2L+ no longer recommended.

5.2 Key Conference Readouts (2024-2025, Down-Weighted Labeling)

The following entries serve only as candidate pool pending formal peer review and do not enter the main database. Items with PMIDs have been promoted.

ADRIATIC OS update (ASCO 2024 LBA5 → 2024-09 NEJM [PMID 39268857]): LS-SCLC cCRT + durvalumab consolidation mOS 55.9 vs 33.4 months — promoted to main database
DeLLphi-301 long-term follow-up (WCLC 2024 / ESMO 2024 oral): tarlatamab 10 mg long-term follow-up ORR + DoR maintained stable; does not change NEJM primary PMID 37861218 data
DeLLphi-302 (tarlatamab 2L+ placebo-controlled phase III): expected 2026 H2 primary readout, NCT05740566 enrollment complete — will provide first phase III head-to-head evidence for tarlatamab vs topotecan / lurbinectedin
ETER701 updated OS (ASCO 2024 / ESMO 2024): benmelstobart + anlotinib + EC four-drug regimen ES-SCLC 1L mOS 19.3 months — promoted to main database
DURABLE OS readout (expected 2025): durvalumab + anlotinib maintenance primary results still pending peer review; PMID 37947242 is protocol paper

5.3 Ongoing Phase III (Selected 2025-2028 Readouts)

DeLLphi-304 (NCT06211036) tarlatamab + atezolizumab/durvalumab 1L maintenance vs atezolizumab/durvalumab maintenance — expected 2026-2028 readout, the key trial to rewrite ES-SCLC 1L maintenance standard
DeLLphi-302 (NCT05740566) tarlatamab vs investigator choice (topotecan / lurbinectedin / topotecan + cyclophosphamide) in SCLC 2L — confirms 2L phase III-level evidence
MAVERICK / PRIMALung ES-SCLC post-chemo + IO response PCI vs MRI surveillance — head-to-head RCT, 2027-2028 readout
IMforte (NCT05091567) ES-SCLC 1L post-chemoimmunotherapy atezolizumab ± lurbinectedin maintenance — expected 2026 readout
Multiple DLL3 ADCs / CAR-T / other BiTEs (MK-6070 / HPN328 / BI 764532) phase I/II ongoing in SCLC 2L+

6. Intersection Insights and Judgment

6.1 Longitudinal × Horizontal: The 2026 SCLC Landscape Is Shaped by Three Resonances

Stacking the longitudinal paradigm evolution on the horizontal current decision landscape, the 2026 SCLC treatment landscape is actually shaped by three resonance overlays:

Chemotherapy 20-year plateau (mOS 9-10 months) → IO + chemo class effect (mOS 12-15 months + 5y long tail 12%): the EP backbone barely moved from 1999 TURRISI to 2018 IMpower133, and all attempts to add a third drug failed. After IO entered 1L, HR converged in 0.63-0.80 class effect, but median OS only gained 2-5 months — the real structural change is the 5-year OS long tail (IMBRELLA-A 5y 12%, chemo-alone historical 3-4%). Clinical prognosis communication should distinguish the dual-layer structure of “median OS” vs “long tail.”
LS-SCLC ADRIATIC first upgrade in 30 years + ES-SCLC class effect saturation + DLL3 BiTE breakthrough as a three-way standoff: 2024 was the densest year in SCLC history — ADRIATIC around May raised LS-SCLC cCRT-post mOS from 33 months to 56 months (+23 months, large delta); tarlatamab approval in May opened a non-chemotherapy new mechanism for 2L+; meanwhile ES-SCLC 1L class effect has saturated (six Chinese PD-1s in parallel, HR 0.63-0.80 differences driven mainly by population/control/follow-up).
“Biological stratification” of IO in SCLC — monotherapy failure vs combination success: CheckMate-032 + KEYNOTE-028/158 IO monotherapy ORR 10-22% but confirmatory phase III failed → FDA withdrew; the same IO after + chemo OS-positive → globally approved. This says SCLC cold-tumor biology (low TMB / immune-desert / no stable neoantigens) sets a low ceiling for IO monotherapy, and chemotherapy debulking + IO checkpoint release + maintenance is the minimum recipe for IO efficacy in SCLC — IO alone does not work in SCLC.

These three resonances together explain a clinical phenomenon: the decision tree for a newly diagnosed SCLC patient in 2026 has 3 more decision layers than in 2018 (LS vs ES staging + whether post-cCRT durvalumab consolidation + 1L IO 6-choose-1 including Chinese PD-1 accessibility branch + 2L tarlatamab DLL3 biomarker stratification).

6.2 Clinical Decision Takeaways (for Junior-Mid Oncologists)

After LS-SCLC cCRT, you must evaluate durvalumab consolidation eligibility: ADRIATIC (PMID 39268857) mOS 55.9 vs 33.4 months is the largest LS-SCLC delta in 30 years. Missing ADRIATIC consolidation = leaving the patient in the cCRT era.
Do not use “concurrent IO + cCRT” in LS-SCLC: NRG LU005 (PMID 41529214) HR 1.03 refuted the PACIFIC-like concurrent path’s replicability in SCLC. cCRT first, then durvalumab sequential.
ES-SCLC 1L IO class effect 6-choose-1: atezolizumab / durvalumab / serplulimab / adebrelimab / tislelizumab / toripalimab HR 0.63-0.80 narrow band; which one to pick depends on accessibility + reimbursement + tolerance. Don’t agonize over “which IO is better” — there is no phase III-level answer.
ES-SCLC 1L long-tail 12% 5-year survival is a key communication point: IMBRELLA-A (PMID 39306923) tells us IO + chemo is not a uniform 2-3 month extension, but gives 12% of patients a 5-year+ long tail. Clinical communication should clearly articulate the dual-layer “median + long tail” prognosis.
2L+ DLL3 testing + tarlatamab preferred: DeLLphi-301 (PMID 37861218) + FDA 2024-05 accelerated approval = first non-chemotherapy new mechanism in SCLC in half a century. DLL3 IHC testing + step-up dosing + CRS management form the three-part foundation of 2026 SCLC 2L basics.
IO monotherapy not recommended in SCLC 2L+: CheckMate-032 + KEYNOTE-028/158 accelerated approvals were withdrawn by FDA 2020-12 / 2021-03 respectively. Only tumor-agnostic MSI-H / TMB-H rare subgroups retained.
Tradeoff between ETER701 four-drug vs three-drug vs two-drug IO + EC: four-drug mOS 19.3 months is historical peak but G3+ TRAE 93% approaches universal; selection requires assessing performance status + comorbidities + tolerance expectations. Don’t default to “highest number = best.”
Attitude toward PCI in the IO era: post-LS-SCLC CR PCI 25 Gy remains standard (PCI99-01); post-ES-SCLC IO response PCI’s status has declined, brain MRI surveillance has become a European alternative — before head-to-head RCTs, PCI vs MRI is a matter of “center preference,” not “right or wrong.”
Transformed SCLC — prioritize clinical trials: EGFR TKI-resistant NSCLC transformed SCLC subgroup is typically excluded by DeLLphi-301 and other trials; standard EP/EC chemo predominates + consider continuing osimertinib to protect residual NSCLC clones.
Seven drug classes essential for SCLC in 2026: durvalumab (LS consolidation + ES 1L) / atezolizumab (ES 1L) / serplulimab + adebrelimab + tislelizumab + toripalimab (Chinese ES 1L 4-choose-1) / benmelstobart + anlotinib (ETER701 four-drug core) / tarlatamab (2L+ DLL3 BiTE) / topotecan (2L non-BiTE backstop) / trilaciclib (myeloprotection) — before 2018 SCLC had only EP + topotecan as two drugs; 2026 already has a 7+ class decision map across 5 pathways.

7. Information Sources

The 30 trials’ metadata in this report were independently cross-verified via PubMed and ClinicalTrials.gov. Each [PMID xxxxxxxx] in the text can be verified directly on PubMed.

Published trials: 28, covering 1999-2026 (PMID verifiable)
Protocol / design papers (primary results pending): 2 (DURABLE PMID 37947242 / TREASURE PMID 36153496 — the latter terminated due to toxicity)
NCCN guideline citations: 30/30 directly hit NCCN Small Cell Lung Cancer V1.2026 reference section or extended evidence base
2020-2025 FDA / NMPA new approvals: 10+ (durvalumab LS consolidation / atezolizumab 1L / serplulimab / adebrelimab / tislelizumab / toripalimab / benmelstobart + anlotinib / tarlatamab / trilaciclib)
2020-2021 FDA withdrawals: 2 (nivolumab SCLC 3L / pembrolizumab SCLC 3L — confirmatory phase III failed)
2024-2026 key conference readouts: 3 (DeLLphi-301 long-term / DeLLphi-302 phase III expected 2026 / ETER701 updated OS)
Research gaps: 10

7.1 Report Body Citation Index (Sorted by PMID Ascending)

The table below lists PMIDs bracket-cited in the body, each clickable on PubMed for verification.

PMID	Trial / Paper	Year	Journal	Body location §x.x
9920950	INT-0096 (TURRISI 1999)	1999	N Engl J Med	§2.1 / §3.1
10080612	TOPOTECAN-ORIGINAL-PHASE2	1999	J Clin Oncol	§2.2 / §3.4
15923572	NIELL-2002-INTERGROUP	2005	J Clin Oncol	§2.2
17135646	OBRIEN-TOPOTECAN-2006	2006	J Clin Oncol	§2.2 / §3.4
17699816	SLOTMAN-PCI-2007	2007	N Engl J Med	§2.3 / §3.3
19386548	PCI99-01	2009	Lancet Oncol	§2.3 / §3.1 / §3.3
25230595	CREST (SLOTMAN-2015)	2015	Lancet	§2.3 / §3.3
27269741	CHECKMATE-032	2016	Lancet Oncol	§2.5 / §3.4 / §5.1
28642008	CONVERT	2017	Lancet Oncol	§2.1 / §3.1
30280641	IMPOWER133	2018	N Engl J Med	§2.4 / §3.2
30988825	EL-PHASE3-CHINA	2019	Oncol Lett	§2.2 / §3.2
31590988	CASPIAN	2019	Lancet	§2.4 / §3.2
31870883	KEYNOTE-028-158	2020	J Thorac Oncol	§2.5 / §3.4 / §5.1
33545387	RTOG-0212-HIPPO (Belderbos 2021)	2021	J Thorac Oncol	§2.3 / §3.3
35576956	CAPSTONE-1	2022	Lancet Oncol	§2.4 / §3.2 / §5.1
36153496	TREASURE	2022	BMC Cancer	§2.5 / §3.5
36166026	ASTRUM-005	2022	JAMA	§2.4 / §3.2 / §5.1
36623230	CALGB-30610 / RTOG-0538	2023	J Clin Oncol	§2.1 / §3.1
37861218	DELLPHI-301	2023	N Engl J Med	§2.5 / §3.4 / §5.1 / §6.2
37947242	DURABLE (protocol)	2023	Clin Respir J	§2.5 / §3.5
38224653	TRACES	2024	Lung Cancer	§2.5 / §3.2 / §5.1
38460751	RATIONALE-312	2024	J Thorac Oncol	§2.4 / §3.2 / §5.1
38992123	ETER701	2024	Nat Med	§2.4 / §3.2 / §5.1
39146944	YU-2024-HYPERFRAC	2024	Lancet Respir Med	§2.1 / §3.1
39268857	ADRIATIC	2024	N Engl J Med	§2.1 / §3.1 / §5.1 / §6.2
39306923	IMBRELLA-A (IMpower133 5y)	2024	Lung Cancer	§2.4 / §3.2 / §6.2
39541202	EXTENTORCH	2025	JAMA Oncol	§2.4 / §3.2 / §5.1
40609842	MATCH-TRIAL-SCLC	2026	Int J Radiat Oncol Biol Phys	§2.5 / §3.5
40934933	DELLPHI-303	2025	Lancet Oncol	§2.5 / §3.5 / §5.3
41529214	NRG-LU005	2026	J Clin Oncol	§2.1 / §3.1

7.2 Verification Conventions

Each PMID is directly accessible via https://pubmed.ncbi.nlm.nih.gov/{PMID}/ for verification
Each NCT id is accessible via https://clinicaltrials.gov/study/{NCT_id}/
Conference abstracts (ASCO / ESMO / WCLC) are retrieved via the official meeting systems; all conference citations in this report are “down-weighted” — not peer-reviewed, final data subject to journal publication
DURABLE + TREASURE cited as protocol / design paper PMIDs; entries will be updated once primary efficacy manuscripts are published
If a PMID in this report is found to differ from PubMed on trial name / year / conclusion, corrections are welcome

Clinical Trial Timelines Here

Chinese: /trials/sclc/ English: /en/trials/sclc/

Each trial has an independent detail page including:

Complete intervention / comparator regimens
Primary endpoint values + 95% CI
Key findings + clinical significance
Clickable links to PMID / NCT originals

30 trials · 5 paradigms · 1999 to 2026 · synchronized with NCCN Small Cell Lung Cancer V1.2026.

Closing

SCLC has completed a unique evolutionary arc over the past 27 years — from 1999 TURRISI INT-0096 establishing LS-SCLC cCRT + BID 45 Gy, through the pre-2018 ES-SCLC 1L EP-backbone 20-year plateau with mOS stable at 9-10 months, to 2018 IMpower133 and 2019 CASPIAN opening the IO marginal-victory breakthrough with HR converging in 0.70-0.73 class effect.

2024 was the densest year in SCLC history: ADRIATIC upgraded LS-SCLC’s 30-year SoC to cCRT + durvalumab consolidation (mOS 55.9 vs 33.4 months, +23-month large delta); DeLLphi-301 tarlatamab received FDA accelerated approval, becoming the first non-chemotherapy non-IO new mechanism in SCLC in half a century; meanwhile five Chinese PD-1 / PD-L1 phase IIIs (ASTRUM-005 / CAPSTONE-1 / RATIONALE-312 / EXTENTORCH / ETER701) pushed ES-SCLC 1L into a “flourishing” era.

This “20-year plateau + IO marginal victory + DLL3 BiTE breakthrough” three-stage pattern is entirely different from NSCLC’s “5 paradigm shifts + 10 drivers all entering 1L + IO rewriting the backbone.” The driving force is SCLC’s unique biology — no unified driver mutation + neuroendocrine differentiation + low TMB + cold tumor + rapid chemoresistance + MYC/ASCL1/NEUROD1/POU2F3/YAP1 molecular subtype heterogeneity. SCLC’s paradigm breakthrough is not “finding a driver gene” but “finding a targetable cell-surface molecule (DLL3) + new mechanism (BiTE).”

For a newly diagnosed SCLC patient in 2026, the core decision-tree branchpoints are “first stage (LS vs ES) → post-cCRT durvalumab consolidation yes/no → 1L IO 6-choose-1 including Chinese accessibility branch → 2L DLL3 biomarker testing + tarlatamab preferred → PCI vs MRI per center preference.”

The value of this report lies not in “enumerating all trials” (PubMed can do that), but in compressing 27 years of evolution + current decisions + unresolved gaps into the cognitive bandwidth of a single reading. Next time you face a newly diagnosed SCLC patient, every branchpoint in the decision tree has this map to check, trace, and interrogate.

Clinician × AI = Research Superpower + Clinical Decision Amplifier

—— Dual Brain Lab · 2026-04-21

NSCLC Clinical Trial Timeline · 25-Year Evolution Map

Fri, 17 Apr 2026 00:00:00 +0000

NSCLC Clinical Trial Timeline · In-depth Report

Coverage: 111 published landmark trials (all PMID-traceable) + 90 ongoing phase III + 20 FDA/NMPA 2024-2026 approvals + 21 key conference readouts

Curated by Dual Brain Lab (csilab.net)

1. One-Sentence Definition

This report maps the systemic therapy of non-small cell lung cancer (NSCLC) over the past 25 years (2002–2026) through the landmark clinical trials cited in the current NCCN NSCLC and CSCO NSCLC 2025 guidelines — providing frontline clinicians in 2026 a traceable full-view map for the “who, what, and why” of decision-making.

Iron rule: every datapoint in every trial traces back to PubMed (PMID) or ClinicalTrials.gov (NCT id). Each [PMID xxxxxxxx] in the body opens directly to PubMed for source verification.

2. Longitudinal: Five-Paradigm Evolution Timeline

NSCLC systemic therapy has gone through five paradigm shifts in the past 25 years: the chemotherapy plateau was broken by driver mutations → TKIs (tyrosine kinase inhibitors) climbed from 2L to 1L to adjuvant → immune checkpoint inhibitors (ICIs) rewrote 2L and then 1L → IO-chemo became the new backbone → perioperative IO rewrote the treatment strategy for resectable disease.

Each shift has 3–5 phase III trials that pushed the previous standard of care (SoC) to second line.

2.1 Chemotherapy Plateau (2002–2015): Established, Challenged, Replaced

Story: The OS median of chemotherapy doublets was locked at ~8 months by ECOG 1594 in 2002. That ceiling stood until driver mutations and checkpoint inhibitors finally broke it.

ECOG 1594 [PMID 11784875] (Schiller 2002 NEJM, N=1207): four platinum doublets randomized — cis+pac vs cis+gem vs cis+doc vs carbo+pac. All four OS curves completely overlapped, mOS ~7.9 months, 1-year OS 33%. The result was both a starting point and a ceiling — “no matter which doublet you pick, it doesn’t matter.”
TAX 326 [PMID 12837811] (Fossella 2003 JCO, N=1218): docetaxel+cis slightly better than navelbine+cis, mOS 11.3 vs 10.1 months. Expanded doublet options but did not break the ceiling.
JMDB / Scagliotti 2008 [PMID 18506025] (N=1725): in non-squamous NSCLC, cis+pemetrexed beat cis+gemcitabine (mOS 11.8 vs 10.4 months) — the first phase III evidence for histology-stratified therapy. From that point on, “non-squamous takes pemetrexed” entered the guidelines.
PARAMOUNT [PMID 22341744] (Paz-Ares 2012 Lancet Oncol): pemetrexed maintenance significantly extended PFS, establishing the 2012 “induction + maintenance” standard for non-squamous NSCLC.

Takeaway: the chemo backbone was refined between 2002 and 2012 (doublet → histology stratification → maintenance), but the OS ceiling did not move. After 2015, with IPASS behind, driver-negative + squamous — the “hard-to-treat” subgroups — finally got breakthroughs from IO.

2.2 EGFR TKI Era (2009–2026): 2L → 1L → Adjuvant → Unresectable III → Combo

Story: EGFR-mutation TKI therapy is the prototype story of precision oncology in lung cancer. Each TKI generation pushed median PFS ~1.5× higher, and every push came with a pivotal phase III.

IPASS [PMID 19692680] (Mok 2009 NEJM, N=1217): gefitinib vs carbo+pac in an East Asian lung adenocarcinoma population. Overall HR 0.74, but EGFR-mutant subgroup HR 0.48 and wild-type subgroup HR 2.85. The “EGFR mutation test → stratified therapy” clinical paradigm was born here.
OPTIMAL [PMID 21783417] (Zhou 2011 Lancet Oncol) + EURTAC [PMID 22285168]: erlotinib vs chemotherapy in EGFRm 1L phase III, PFS doubled (mPFS 13.1 vs 4.6 months). 2nd-gen TKI (afatinib) LUX-Lung 3/6 consolidated further.
FLAURA [PMID 29151359] (Soria 2018 NEJM, N=556): osimertinib (3rd-gen EGFR TKI) vs 1st/2nd-gen in EGFRm 1L. mPFS 18.9 vs 10.2 months, HR 0.46, with stronger CNS activity. 2019 FLAURA OS update [PMID 31751012] was the first TKI to show OS benefit (mOS 38.6 vs 31.8 months, HR 0.80).
ADAURA [PMID 32955177] (Wu 2020 NEJM, OS 2023 [PMID 37272535]): resectable IB-IIIA EGFRm NSCLC, 3-year adjuvant osimertinib vs placebo. DFS HR 0.17, OS HR 0.49. Changed EGFRm early recurrence from “wait then treat” to “eradicate residual disease.”
LAURA [PMID 38828946] (Lu 2024 NEJM): unresectable stage III EGFRm NSCLC, osimertinib consolidation post-CRT (chemoradiation) vs placebo. mPFS 39.1 vs 5.6 months, HR 0.16. Filled the gap that PACIFIC left open for EGFRm patients unsuitable for durvalumab.
FLAURA2 [PMID 37937763] (Planchard 2023 NEJM) + MARIPOSA [PMID 38924756] (Cho 2024 NEJM, OS update 2025 [PMID 40923797]): two combo regimens — osi+chemo and amivantamab+lazertinib — pushed mPFS to 25.5 / 23.7 months, beating osi monotherapy’s 16.6 months. MARIPOSA OS HR 0.75, 3-year OS 60% vs 51% — the first mature 1L EGFRm OS benefit.
MARIPOSA-2 [PMID 37879444] + TROPION-Lung01 [PMID 39250535] (Ahn 2025 JCO): ADC (antibody-drug conjugate) strategies for post-osimertinib resistance. Dato-DXd PFS HR 0.38 in the EGFR-mutant subgroup.
SACHI [PMID 41544643] (Lu 2026 Lancet): in the post-osi MET-amplified subgroup, savolitinib+osimertinib vs chemotherapy. mPFS 8.3 vs 3.6 months, HR 0.34. First randomized controlled evidence for “treat-by-resistance-mechanism.”

Takeaway: EGFRm therapy has evolved from the 2009 “TKI vs chemo” binary to a 2026 four-dimensional decision tree — “stage × line × resistance mechanism × tolerance.” Combo (FLAURA2 / MARIPOSA) and mono (FLAURA) coexist; the choice between them comes down to tolerance and disease burden.

2.3 Non-EGFR Drivers (2014–2026): From Basket to Dedicated 1L

Story: Eight drivers — ALK, ROS1, MET, KRAS, HER2, RET, BRAF, NTRK — each walked the path “accelerated approval on phase 2 → pivotal phase 3 → pushed into 1L” between 2014 and 2026, but at very different speeds.

Driver	Key trials (PMID)	Line
ALK	PROFILE 1014 [PMID 25470694] (2014) → ALEX [PMID 28586279] (2017) → CROWN [PMID 33207094] (2020, lorlatinib) → ALINA [PMID 38598794] (2024, adjuvant alectinib)	Fully in 1L + adjuvant
ROS1	PROFILE 1001 → TRIDENT-1 [PMID 38197815] (2024, repotrectinib 1L ORR 79%)	1L (repotrectinib replaces crizotinib)
MET ex14	GEOMETRY mono-1 [PMID 32877583] (capmatinib 2020) / VISION [PMID 32469185] (tepotinib 2020)	Phase II accelerated approval; no phase III; 1L still contested
KRAS G12C	CodeBreaK 100 [PMID 34096690] → CodeBreaK 200 [PMID 36764316] (sotorasib 2L) → KRYSTAL-12 [PMID 40783289] (adagrasib 2L) → divarasib 1/2 [PMID 37611121] (phase 3 pending)	2L only
HER2 exon 20	DESTINY-Lung02 [PMID 37694347] (T-DXd 2L, ORR 49%) → Beamion LUNG-1 [PMID 40293180] (zongertinib 2L, ORR 71%)	2L; 1L still chemo-IO
RET	LIBRETTO-431 [PMID 37870973] (selpercatinib 1L vs chemo+pembro, mPFS 24.8 vs 11.2 months)	1L established
BRAF V600E	PHAROS [PMID 37270692] (encorafenib+binimetinib 1L ORR 75%)	1L
NTRK	larotrectinib / entrectinib tumor-agnostic approvals	Basket, accelerated
EGFR exon 20 insertion	PAPILLON [PMID 37870976] (amivantamab+chemo vs chemo 1L, mPFS 11.4 vs 6.7 months)	1L

Takeaway: speed of 1L entry ranks as ALK > EGFR common > EGFR ex20 > ROS1 > RET > BRAF > MET ex14 ≈ HER2 ex20 > KRAS G12C. KRAS G12C is still stuck at 2L — sotorasib and adagrasib both failed to show OS benefit over docetaxel in phase III. Divarasib’s early data (ORR 53%, mPFS 13 months) may be the next 1L-KRAS breakthrough.

2.4 IO 1L (2015–2024): From 2L Trials to Backbone Rewrite

Story: IO (anti-PD-1 / anti-PD-L1) got its first NSCLC evidence in 2015 with CheckMate-017 / 057 (2L), then KEYNOTE-024 (2016) pushed it to 1L monotherapy for PD-L1 high expressors, and finally KEYNOTE-189 (2018) wrote IO+chemo into the 1L backbone.

CheckMate-017 [PMID 26028407] (squamous) + CheckMate-057 [PMID 26412456] (non-squamous) (Brahmer / Borghaei 2015 NEJM): nivolumab vs docetaxel in 2L NSCLC. OS HR 0.59 (sq) / 0.73 (non-sq). IO enters lung cancer history.
KEYNOTE-010 [PMID 26712084] (Herbst 2016 Lancet): pembrolizumab vs docetaxel in PD-L1 ≥1% 2L. Confirmed PD-L1 as a stratification biomarker.
KEYNOTE-024 [PMID 27718847] (Reck 2016 NEJM, N=305): pembrolizumab monotherapy vs chemotherapy in PD-L1 TPS ≥50% 1L. mOS 30.0 vs 14.2 months, HR 0.60. IO monotherapy 1L established. The 5-year update [PMID 33872070] shows 5-year OS 31.9% vs 16.3% — a beautifully preserved tail.
KEYNOTE-189 [PMID 29658856] (Gandhi 2018 NEJM, N=616): pembrolizumab + pemetrexed + platinum vs placebo+chemo in non-squamous 1L (regardless of PD-L1). OS HR 0.49 (0.38–0.64), OS benefit in every PD-L1 subgroup including TPS<1%. The “~8-month ceiling” of the chemo plateau was finally shattered by the IO-chemo backbone. 5-year update [PMID 36809080]: 5y OS 19.4% vs 11.3%, TPS<1% HR 0.55.
KEYNOTE-407 [PMID 30280635] (Paz-Ares 2018 NEJM): pembro+carbo+(nab-)pac vs placebo+chemo in squamous 1L. 5-year OS 18.4% vs 9.7% [PMID 36735893]. Squamous — previously stuck with only docetaxel — was rewritten.
IMpower110 [PMID 32997907] / IMpower130 / IMpower132 / IMpower150 [PMID 29863955]: atezolizumab combos. IMpower150 (atezo+bev+chemo) retains a niche role in EGFR/ALK post-TKI and liver-metastases subgroups.
CheckMate-227 [PMID 31562796] (Hellmann 2019 NEJM, 5y update 2023 [PMID 36223558]): nivolumab+ipilimumab as a “chemo-sparing” IO-IO regimen. In the PD-L1<1% subgroup, 5y OS 19% vs 7%, HR 0.72.
CheckMate 9LA [PMID 33476593] (Paz-Ares 2021 Lancet Oncol, 5y [PMID 39270380]): nivo+ipi + 2 cycles of chemo — chemo-sparing but keeping the early tumor-debulking effect of chemo, OS HR 0.66.
POSEIDON [PMID 36327426]: durvalumab + tremelimumab + chemo. In the PD-L1<1% subgroup, tremelimumab adds ~3 months of OS.

Takeaway: the core branching of 1L IO selection in 2026 is histology (sq / non-sq) × PD-L1 (<1% / 1-49% / ≥50%) × performance status × combo tolerance. KEYNOTE-189 + KEYNOTE-407 cover nearly the entire PD-L1 spectrum in non-sq and sq; CheckMate-227 / 9LA serve as “don’t want chemo” alternatives; POSEIDON offers an intensified option for PD-L1<1%. Chinese PD-1 agents (sintilimab ORIENT-11 [PMID 35917647], tislelizumab, camrelizumab) dominate in subgroups driven by price and accessibility.

2.5 Perioperative IO (2021–2026): From Adjuvant-Only to Dual-Punch

Story: IO therapy for resectable NSCLC has had 6–8 phase III readouts over 5 consecutive years since 2021. The strategy evolved from “adjuvant only” (post-op) to “neoadjuvant only” (pre-op), and on to “perioperative” (= pre-op + post-op).

IMpower010 [PMID 34555333] (Felip 2021 Lancet, 5y update [PMID 40446184]): resectable IB-IIIA, 1-year adjuvant atezolizumab vs BSC. DFS and OS both benefit in the PD-L1 ≥50% subgroup; benefit unclear for PD-L1 <50%.
KEYNOTE-091 [PMID 36108662] (O’Brien 2022 Lancet Oncol): adjuvant pembrolizumab vs placebo. DFS HR 0.76 overall, but benefit inconsistent across PD-L1 subgroups.
CheckMate 816 [PMID 35403841] (Forde 2022 NEJM, OS 2025 [PMID 40454642]): neoadjuvant nivolumab+chemo × 3 cycles vs chemo alone. pCR (pathological complete response) 24% vs 2.2%, EFS (event-free survival) HR 0.63, OS HR 0.72. First phase III OS benefit in the neoadjuvant setting.
KEYNOTE-671 [PMID 37272513] (Wakelee 2023 NEJM, OS 2024 Lancet [PMID 39288781]): perioperative (neoadjuvant pembro+chemo × 4 → post-op pembro × 13). EFS HR 0.58, OS HR 0.72 — first perioperative trial with OS benefit.
AEGEAN [PMID 37870974] (Heymach 2023 NEJM): perioperative durvalumab+chemo. EFS HR 0.68, pCR 17.2% vs 4.3%.
CheckMate 77T [PMID 38749033] (Cascone 2024 NEJM): perioperative nivo+chemo. EFS HR 0.58, pCR 25.3% vs 4.7%.
Neotorch [PMID 38227033] (Lu 2024 JAMA, China): perioperative toripalimab+chemo in stage II-III. Stage III subgroup EFS HR 0.40.
RATIONALE-315 [PMID 39581197] (Yue 2025 Lancet Respir Med): perioperative tislelizumab+chemo. pCR 40.7% vs 5.7%, EFS HR 0.56.

Takeaway: by 2026 the SoC for resectable stage II-IIIB NSCLC is firmly perioperative IO-chemo (3-4 cycles neoadjuvant + ≥1 year adjuvant IO), with pCR confirmed as a strong surrogate for EFS / OS across multiple trials. The one exception: EGFRm → ADAURA (3-year adjuvant osimertinib) and ALK+ → ALINA (adjuvant alectinib) — these two driver-positive subgroups should avoid perioperative IO.

3. Cross-Sectional: 2026 Decision Landscape (Six Dimensions)

Six dimensions cover the full decision landscape — 1L, important 2L, early stage, PD-L1 low, post-resistance, and rare drivers. Each includes mainstream regimens, areas of controversy, head-to-head / NMA (network meta-analysis) evidence, and current NCCN/CSCO tiers.

3.1 1L IO-combo Selection (EGFR/ALK-WT, PD-L1 ≥1%)

2026 mainstream: pembro+chemo (KEYNOTE-189 non-sq / KEYNOTE-407 sq) remains the global IO-chemo backbone across the PD-L1 spectrum. For PD-L1 TPS ≥50% fit patients, pembro monotherapy (KEYNOTE-024) is still guideline-preferred, but clinical practice drifts toward combo (deeper early response + less “in-hindsight regret”). IMpower150 now only applies in liver-mets and EGFR post-TKI niches. CheckMate 9LA and POSEIDON serve as chemo-sparing / CTLA-4-adding alternatives.

Key branchpoints:

Subgroup	First choice	Alternative
Non-sq PD-L1 ≥50%	pembro mono (KN-024, 5y OS 31.9%) or pembro+pem-plat (KN-189)	CheckMate-227 (PD-L1 ≥1%)
Non-sq PD-L1 1–49%	pembro+pem-plat (KN-189)	CheckMate 9LA
Squamous full PD-L1	pembro+carbo+(nab-)pac (KN-407, 5y OS 18.4% vs 9.7%)	nivo+ipi+chemo (CM-9LA)
Non-sq PD-L1 <1%	pembro+pem-plat (KN-189 TPS<1% 5y HR 0.55)	CheckMate 9LA / CheckMate-227

Head-to-head / NMA:

2025 NMA [PMID 41486797]: pembrolizumab + chemotherapy ranked highest in non-sq (SUCRA HR 0.76); in squamous, nivo+ipi+chemo ranked top (SUCRA 78.3%).
KEYNOTE-189 5y [PMID 36809080] vs KEYNOTE-407 5y [PMID 36735893]: both maintain >5-year OS benefit; squamous HR 0.71 trails non-sq HR 0.60.

Controversies: for PD-L1 ≥50%, is IO-mono ≈ IO-chemo? No H2H; cross-trial data suggest “combo has better PFS but OS converges over time.” ORIENT-11 (domestic sintilimab) vs KEYNOTE-189: large differences in population, comparator arm, and PD-L1 assay mean formal equivalence is impossible — yet in price- and access-driven Chinese practice, ORIENT-11 has already replaced it widely.

NCCN 2026: histology-matched pembro+chemo = Category 1 preferred (non-sq + sq). Pembro mono = Cat 1 only for TPS ≥50%. CheckMate 9LA = Cat 1 alternative.

CSCO 2025: pembrolizumab / sintilimab / tislelizumab + chemo = Level I recommendation (non-sq); pembrolizumab / tislelizumab / camrelizumab + chemo = Level I (squamous); PD-L1 TPS ≥50% pembro mono = Level I.

3.2 EGFRm 1L: Three-Way Fight Between Mono and Combo

2026 mainstream: EGFRm 1L has shifted from osimertinib-monotherapy era into the combo era. FLAURA2 (osi+pem-plat, mOS 47.5 months [PMID 41104938]) and MARIPOSA (ami+laz, OS HR 0.77 [PMID 40923797]) both beat osi mono on OS. Osi mono (FLAURA) survives for patients “not fit for combo” thanks to its low toxicity. MARIPOSA-2 (post-osi progression, ami+chemo ± laz [PMID 37879444]) is the new post-osi standard.

Key branchpoints:

Subgroup	Recommended
Fit + high burden / L858R	FLAURA2 or MARIPOSA (combo advantage most pronounced)
Exon 19del	MARIPOSA numerical benefit slightly larger (HR ~0.65)
CNS met at baseline	MARIPOSA intracranial PFS HR 0.69; osi mono also has sufficient CNS activity
Elderly / low burden	osi mono (FLAURA) — avoids chemo toxicity (FLAURA2 G3+ AE 64%) and ami infusion / VTE burden
Post-osi progression	MARIPOSA-2 (ami+carbo-pem ± laz) Cat 1; MET-amplified → SACHI (savolitinib+osi) [PMID 41544643]

Head-to-head / NMA:

No direct FLAURA2 vs MARIPOSA H2H. Cross-trial: mPFS 25.5 vs 23.7 months, 3y OS 63% vs 60%, but toxicity profiles are entirely different (ami: rash / VTE / infusion; chemo: marrow / neuro).
MARIPOSA VTE issue: protocol amended to require prophylactic anticoagulation in the first 4 months; real-world implementation is uneven.

Controversy: is the combo OS benefit worth the doubled toxicity? The answer is patient-specific — there is no universal winner; patient choice is the core variable.

NCCN 2026: EGFRm 1L Cat 1 options = (a) ami+laz (b) osi+pem-plat (c) osi mono — all three listed without ranking.

CSCO 2025: osi mono = Level I (wide accessibility); FLAURA2 + amivantamab-based combos = Level II (pending NRDL inclusion).

3.3 Perioperative IO: Choosing Among Three Strategies

2026 mainstream: perioperative (3-4 cycles pre-op IO-chemo + ≥1 year post-op IO) has replaced adjuvant-only and neoadjuvant-only as SoC for resectable stage II-IIIB NSCLC. Five phase III trials — KEYNOTE-671 / AEGEAN / CheckMate 77T / Neotorch / RATIONALE-315 — consistently show EFS HR 0.56–0.68, and OS benefit has emerged (KEYNOTE-671 OS HR 0.72 [PMID 39288781]).

Key branchpoints:

Subgroup	Recommended
Stage II-IIIB PD-L1 ≥1% resectable	perioperative pembro+chemo (KN-671) or nivo+chemo (CM-77T) preferred
Stage II-IIIB PD-L1 <1% resectable	perioperative IO-chemo still benefits but magnitude is smaller (CM-77T PD-L1<1% EFS HR 0.73); weigh IO duration
Stage IB-IIA small tumor	neoadjuvant-only (CM-816) reasonable; or post-op adjuvant IMpower010 / KN-091
EGFRm resectable	adjuvant osimertinib (ADAURA DFS HR 0.17, OS HR 0.49). Do not use perioperative IO (all 5 perioperative trials excluded EGFRm)
ALK+ resectable	adjuvant alectinib (ALINA DFS HR 0.24 [PMID 38598794]). Same rule — avoid IO
Borderline unresectable	perioperative IO-chemo may convert to resectable; multidisciplinary decision

Controversies:

Neoadjuvant-only vs perioperative — no direct RCT. Indirect comparisons favor perioperative, but adjuvant IO adds 6-9 months of treatment and toxicity.
pCR as surrogate: strongly correlated with EFS / OS in KEYNOTE-671 and CM-816, but FDA has not formally accepted it as a standalone endpoint for accelerated approval.
ctDNA clearance as a new surrogate: in KN-671, pCR rate was 47% in ctDNA-negative patients vs 8% in ctDNA-positive.
Does everyone need adjuvant IO? De-escalation trials are in design (continue adjuvant based on ctDNA or pCR status).

NCCN 2026: resectable stage II-IIIB (EGFR/ALK-WT) = perioperative pembro+chemo (KN-671) / nivo+chemo (CM-77T) / durva+chemo (AEGEAN) Cat 1 preferred.

3.4 PD-L1 TPS <1% Subgroup

Mainstream: IO-chemo combo (KEYNOTE-189 non-sq TPS<1% 5y HR 0.55; KEYNOTE-407 sq TPS<1% HR ~0.79) remains standard. CheckMate-227 (nivo+ipi in PD-L1<1%, 5y OS 19% vs 7%) is a chemo-sparing alternative. POSEIDON shows tremelimumab adds ~3 months of OS in PD-L1<1% but is regionally constrained. Pure chemo is now inferior in every subgroup.

Controversies:

Is the KEYNOTE-189 PD-L1 TPS<1% OS benefit real IO contribution or immortal-time bias? The 5-year follow-up strengthens the IO signal, but subgroup HR confidence intervals are wide.
Do chemo-sparing IO-IO regimens (CM-227 / CM-9LA) truly beat full-dose IO-chemo in PD-L1<1%? No direct H2H; 9LA has higher immune toxicity but less marrow toxicity.
Is tremelimumab’s ~3-month OS gain in POSEIDON worth the toxicity? Real-world uptake is low.
PD-L1 <1% is a heterogeneous population (true biology vs assay false-negative) — biomarker refinement is a gap.

3.5 EGFR / ALK Post-Resistance

2026 mainstream: post-osi splits into resistance-mechanism-matched paths —

MET-amplified (12–30%) → savolitinib+osi (SACHI [PMID 41544643], mPFS 8.3 months), NMPA-approved 2026; global use is off-label.
MET overexpressing (no amplification) → telisotuzumab vedotin (LUMINOSITY [PMID 38843488], ORR 35%), FDA accelerated (Emrelis).
Unselected broad-spectrum → MARIPOSA-2 ami+chemo±laz (mPFS 6.3–8.3 months), Cat 1.
Any EGFRm post-chemo → datopotamab deruxtecan (TROPION-Lung01 [PMID 39250535], EGFRm subgroup PFS HR 0.38).
CNS-only progression → local therapy (SRS) + continue osi.

Post-lorlatinib ALK+: no approved targeted therapy. Chemo+IO is the fallback. 4th-gen ALK TKIs (NVL-655 etc.) remain in early-phase trials.

Important update: patritumab deruxtecan (HER3-DXd) HERTHENA-Lung01 [PMID 37689979] confirmed activity (ORR 29.8%), but Daiichi discontinued phase 3 NSCLC development in 2024 — not commercially available in 2026.

3.6 Rare Drivers: 1L Entry Status for 8 Branches

Driver	1L entry?	Key evidence
ALK	In	CROWN 5y PFS 60% [PMID 38819031], lorlatinib best
ROS1	In	TRIDENT-1 repotrectinib ORR 79% [PMID 38197815], best CNS activity
EGFR common	In	osi / osi+chemo / ami+laz, three-way choice
EGFR ex20	In	PAPILLON ami+chemo mPFS HR 0.40 [PMID 37870976]
RET fusion	In	LIBRETTO-431 selpercatinib vs chemo+pembro HR 0.46 [PMID 37870973]
BRAF V600E	In	PHAROS enco+bini ORR 75% [PMID 37270692]
MET ex14	Partial	capmatinib / tepotinib on phase II accelerated approval; no phase III
HER2 ex20	Not yet	2L T-DXd (DESTINY-Lung02) / zongertinib (Beamion LUNG-1); 1L still chemo-IO
KRAS G12C	Not yet	sotorasib (CB-200) / adagrasib (KRYSTAL-12) 2L PFS benefit but OS not significant; divarasib (phase 3 ongoing) may break through
NTRK	Basket	larotrectinib / entrectinib tumor-agnostic accelerated

China approval lag (2026): repotrectinib approved in China 2025 (2 years after US), selpercatinib 2023, amivantamab 2025. Glecirasib (China-domestic KRAS G12C TKI) approved ahead of FDA-divarasib — a rare reversal.

NMPA-only drugs (China-exclusive): aumolertinib (3rd-gen EGFR TKI), furmonertinib, ensartinib, toripalimab, sintilimab, tislelizumab, camrelizumab, sugemalimab, penpulimab, cadonilimab (AK104, PD-1+CTLA-4 bispecific).

4. Research Gaps: 10 Unsolved Clinical Questions

The gaps below are specifically defined questions (not “more research is needed” clichés):

EGFRm 1L: FLAURA2 (osi+chemo) vs MARIPOSA (ami+laz) has no prospective H2H; clinicians are forced into cross-trial comparison while toxicity profiles are entirely different.
PD-L1 TPS<1% NSCLC: is the KEYNOTE-189 PD-L1-negative subgroup OS benefit real IO contribution, or is it confounded by control-arm crossover + immortal-time bias? A dedicated PD-L1-negative RCT is needed.
Perioperative IO de-escalation: is the adjuvant IO phase necessary for all patients, or only for ctDNA-positive / non-pCR patients? De-escalation trials are missing.
Post-lorlatinib ALK+ NSCLC: no approved targeted therapy; ~40% of relapses are driven by compound ALK mutations; 4th-gen ALK TKIs (NVL-655 etc.) in early trials.
KRAS G12C 1L: none of sotorasib / adagrasib / divarasib / glecirasib has phase 3 1L data beating IO-chemo — all remain 2L.
Biomarker-driven ADC sequencing: HER3 / TROP2 / c-MET expression thresholds across Dato-DXd / patritumab-DXd / teliso-V are not standardized; usage is empirical.
Chinese PD-1 inhibitors (sintilimab / tislelizumab / camrelizumab / toripalimab) vs pembrolizumab: each has independent phase 3 data but no H2H; price-vs-outcome decisions have no direct evidence.
PD-L1 IHC assay variability (22C3 vs SP263 vs SP142 vs Dako 28-8): particularly at the TPS 1-49% branching point — unresolved.
IO response and co-mutation effect (STK11 / KEAP1 / SMARCA4 loss): known to reduce IO benefit but not yet routinely incorporated into clinical decision algorithms.
CNS-penetrant next-gen TKIs (lorlatinib / repotrectinib) and SRS / WBRT sequencing: no prospective definition.

5. 2024–2026 Updates

5.1 FDA / NMPA New Approvals (10 key entries of 20)

Drug	Agency	Date	Indication / Supporting trial
datopotamab deruxtecan (Datroway)	FDA	2025-06-23	2L EGFRm NSCLC post-TKI and chemo / TROPION-Lung01
lazertinib + amivantamab (Lazcluze+Rybrevant)	FDA	2024-08-19	1L EGFRm NSCLC / MARIPOSA
repotrectinib (Augtyro)	FDA	2023-11-15 (NSCLC indication expanded 2024)	ROS1+ 1L / TRIDENT-1
tarlatamab (Imdelltra)	FDA	2024-05-16	SCLC (not within NSCLC scope)
zongertinib (Hernexeos)	FDA	2025-07-10	2L HER2-mutant NSCLC / Beamion LUNG-1
savolitinib+osimertinib	NMPA	2026-01	post-osi MET-amplified / SACHI
telisotuzumab vedotin (Emrelis)	FDA	2024-05-14	c-MET high-expressor 2L EGFR-WT NSCLC / LUMINOSITY
aumolertinib	NMPA	2020 (later-line updates 2024)	EGFRm NSCLC (China-exclusive 3rd-gen TKI)
furmonertinib	NMPA	2021	EGFRm NSCLC (China-exclusive 3rd-gen TKI)
neoadjuvant pembrolizumab (KN-671)	FDA	2023-10-16	Perioperative stage II-IIIB NSCLC

(This section shows 10 key approvals; full list of 20 follows chronological order.)

5.2 Key Conference Readouts (2024–2025, Downweighted Labeling)

Entries below are candidate-pool-only until peer-reviewed publication. Those with PMIDs have been promoted to the main library.

LAURA (ASCO 2024 LBA3) [PMID 38828946]: osi consolidation post-CRT, mPFS 39.1 vs 5.6 months, HR 0.16. Fills the PACIFIC gap for stage III EGFRm.
MARIPOSA OS update (ASCO 2025) [PMID 40923797]: ami+laz vs osi OS HR 0.75, 3y OS 60% vs 51%.
FLAURA2 final OS (ESMO 2025) [PMID 41104938]: osi+chemo mOS 47.5 vs 37.0 months.
CheckMate 816 OS (WCLC 2024) [PMID 40454642]: neoadj nivo+chemo OS HR 0.72.
KRYSTAL-12 (ESMO 2024) [PMID 40783289]: adagrasib vs docetaxel 2L KRAS G12C.
SACHI (WCLC 2025) [PMID 41544643]: savo+osi post-osi MET-amplified.

(This section extracts 6 key readouts; the full conference pool has 21 non-peer-reviewed PMIDs.)

5.3 Ongoing Phase III (2025-2026 Expected Readouts)

Selected 3 representatives from 90 ongoing phase III whose primary readout is expected in 2025-2026 and is likely to change practice:

NCT04853342 FORWARD — furmonertinib vs placebo adjuvant EGFRm (Allist, China)
NCT05840016 — AK112 (ivonescimab, PD-1+VEGF bispecific) + chemo vs tislelizumab+chemo in squamous NSCLC 1L (Akeso)
NCT06617416 — AK104 (cadonilimab) vs sugemalimab in unresectable stage III NSCLC consolidation
(This section shows 3 representative readouts expected in 2025-2026; the full pool has 90 ongoing phase III.)

AK112 (ivonescimab) is the biggest 2024-2025 dark horse in Chinese lung cancer — the PD-1+VEGF bispecific is challenging pembro across multiple domestic phase III trials. HARMONi-2 (2024 WCLC) H2H: ivonescimab+chemo vs pembro+chemo mPFS 11.14 vs 5.82 months. If overseas replication succeeds, the IO-chemo backbone may be rewritten.

6. Crosspoint Insights

6.1 Longitudinal × Cross-Sectional: Three Resonances Shaping 2026

Overlaying longitudinal paradigm evolution on the cross-sectional decision landscape reveals the 2026 NSCLC picture as three layered resonances:

Chemo ceiling (mOS ~8 months) → IO-chemo backbone (mOS ~22 months) pushed driver-negative + full-PD-L1-spectrum NSCLC to 2-3× OS.
Driver stratification from 2–3 (EGFR/ALK) → 8–10 (+ ROS1/MET/KRAS/HER2/RET/BRAF/NTRK/ex20) decomposed “unselected” NSCLC into 10+ subdiseases.
Early-stage NSCLC now covered by adjuvant osi (ADAURA) + perioperative IO-chemo + adjuvant alec (ALINA) — resectable NSCLC moved from “cut and pray” to “treat by subtype.”

Together these three resonances explain a clinical phenomenon: the 1L decision tree for a newly diagnosed stage IV NSCLC patient in 2026 has 3 more decision layers than in 2016 (driver panel → PD-L1 stratification → combo intensity → China accessibility branch).

6.2 Clinical Takeaways for Junior-Mid Oncologists

“Panel first, then decide” is SoC — opening IO-chemo in 2026 without comprehensive molecular profiling is wrong; missing EGFR / ALK gives the patient the wrong regimen.
Do not give perioperative IO to EGFRm / ALK+ — all five perioperative trials excluded them. These two driver-positive subgroups go adjuvant osi / alec instead.
PD-L1 TPS 50% is not “IO-mono exclusive” — IO-chemo data in fit patients are more consistent, especially for non-squamous.
Post-osi requires typing before treating — MET-amplified → SACHI, MET-overexpressing → teliso-v, broad-spectrum → MARIPOSA-2 or Dato-DXd.
KRAS G12C is still 2L only — do not use in 1L; 1L remains IO-chemo based on histology + PD-L1.
Perioperative therapy in 2026 is SoC that was unthinkable 5 years ago — 3-4 cycles of pre-op IO-chemo is the new starting point.
Chinese PD-1 accessibility × price: sintilimab / tislelizumab / camrelizumab / toripalimab are reasonable choices backed by their own phase III data but without H2H vs pembro. Insurance- and accessibility-driven decisions are the real-world norm.
AK112 (ivonescimab) may be the next breakthrough — but until global replication succeeds, treat it cautiously.

7. Sources

The 111-trial metadata in this report is independently verified via PubMed and ClinicalTrials.gov. Each [PMID xxxxxxxx] in the body can be opened directly on PubMed for verification.

Published trials: 111, covering 2002-2026
Ongoing phase III: 90 (primary completion 2025-2026)
FDA/NMPA 2024-2026 approvals: 20
2024-2025 key conference readouts: 21 (those with PMID available have been promoted to published trials)
Research gaps: 10

7.1 PMID Reference Table (ascending order)

The table below is the PMID list bracket-cited in the body; each can be clicked through to PubMed for verification.

PMID	Trial / Paper	Year	Journal	Section
11784875	ECOG 1594	2002	NEJM	§2.1 Chemo plateau
12837811	TAX 326	2003	JCO	§2.1
18506025	JMDB / Scagliotti 2008	2008	JCO	§2.1
19692680	IPASS	2009	NEJM	§2.2 EGFR TKI
21783417	OPTIMAL	2011	Lancet Oncol	§2.2
22285168	EURTAC	2012	Lancet Oncol	§2.2
22341744	PARAMOUNT	2012	Lancet Oncol	§2.1
25470694	PROFILE 1014	2014	NEJM	§2.3 ALK
26028407	CheckMate-017	2015	NEJM	§2.4 IO
26412456	CheckMate-057	2015	NEJM	§2.4
26712084	KEYNOTE-010	2016	Lancet	§2.4
27718847	KEYNOTE-024	2016	NEJM	§2.4, §3.1
28586279	ALEX	2017	NEJM	§2.3 ALK
28885881	PACIFIC	2017	NEJM	§2.2
29151359	FLAURA primary	2018	NEJM	§2.2
29658856	KEYNOTE-189 primary	2018	NEJM	§2.4, §3.1
29863955	IMpower150	2018	NEJM	§2.4, §3.1
30280635	KEYNOTE-407 primary	2018	NEJM	§2.4, §3.1
30955977	KEYNOTE-042	2019	Lancet	§3.1
31562796	CheckMate-227 primary	2019	NEJM	§2.4, §3.4
31751012	FLAURA OS	2019	NEJM	§2.2
32469185	VISION tepotinib	2020	NEJM	§2.3, §3.6
32877583	GEOMETRY mono-1 capmatinib	2020	NEJM	§2.3, §3.6
32955177	ADAURA primary	2020	NEJM	§2.2, §3.3
32997907	IMpower110	2020	NEJM	§2.4
33207094	CROWN primary	2020	NEJM	§2.3 ALK
33476593	CheckMate 9LA primary	2021	Lancet Oncol	§2.4, §3.1
33872070	KEYNOTE-024 5y	2021	JCO	§2.4
34096690	CodeBreaK 100	2021	NEJM	§2.3 KRAS
34555333	IMpower010 primary	2021	Lancet	§2.5, §3.3
35403841	CheckMate 816 primary	2022	NEJM	§2.5, §3.3
35917647	ORIENT-11 final OS	2022	JTO	§2.4
36108662	KEYNOTE-091	2022	Lancet Oncol	§2.5, §3.3
36223558	CheckMate-227 5y	2023	JCO	§2.4, §3.4
36327426	POSEIDON primary	2023	JCO	§2.4, §3.1, §3.4
36735893	KEYNOTE-407 5y	2023	JCO	§2.4, §3.1
36764316	CodeBreaK 200	2023	Lancet	§2.3 KRAS, §3.6
36809080	KEYNOTE-189 5y	2023	JCO	§2.4, §3.1, §3.4
37270692	PHAROS enco+bini	2023	JCO	§2.3 BRAF, §3.6
37272513	KEYNOTE-671 primary	2023	NEJM	§2.5, §3.3
37272535	ADAURA OS	2023	NEJM	§2.2, §3.3
37611121	Divarasib phase 1/2	2023	NEJM	§2.3 KRAS, §3.6
37689979	HERTHENA-Lung01	2023	JCO	§2.2, §3.5
37694347	DESTINY-Lung02	2023	JCO	§2.3 HER2, §3.6
37870973	LIBRETTO-431	2023	NEJM	§2.3 RET, §3.6
37870974	AEGEAN primary	2023	NEJM	§2.5, §3.3
37870976	PAPILLON	2023	NEJM	§2.3 EGFR ex20, §3.6
37879444	MARIPOSA-2	2024	Ann Oncol	§2.2, §3.5
37937763	FLAURA2 primary	2023	NEJM	§2.2, §3.2
38197815	TRIDENT-1	2024	NEJM	§2.3 ROS1, §3.6
38227033	Neotorch	2024	JAMA	§2.5, §3.3
38598794	ALINA	2024	NEJM	§2.3 ALK, §3.3
38749033	CheckMate 77T	2024	NEJM	§2.5, §3.3
38819031	CROWN 5y	2024	JCO	§3.6
38828946	LAURA	2024	NEJM	§2.2
38843488	LUMINOSITY teliso-v	2024	JCO	§2.2, §3.5
38924756	MARIPOSA primary	2024	NEJM	§2.2, §3.2
39243945	POSEIDON 5y	2025	JTO	§3.4
39250535	TROPION-Lung01	2025	JCO	§2.2, §3.5
39270380	CheckMate 9LA 5y	2024	JCO	§2.4
39288781	KEYNOTE-671 OS	2024	Lancet	§2.5, §3.3
39362249	GEOMETRY mono-1 final	2024	Lancet Oncol	§3.6
39581197	RATIONALE-315 interim	2025	Lancet Respir Med	§2.5, §3.3
40293180	Beamion LUNG-1 zongertinib	2025	NEJM	§2.3 HER2, §3.6
40446184	IMpower010 5y	2025	JCO	§3.3
40454642	CheckMate 816 OS	2025	NEJM	§2.5
40480428	PHAROS updated	2025	JCO	§3.6
40783289	KRYSTAL-12	2025	Lancet	§2.3 KRAS, §3.6
40923797	MARIPOSA OS	2025	NEJM	§2.2, §3.2
41104938	FLAURA2 OS	2026	NEJM	§2.2, §3.2
41486797	2025 NMA pembro+chemo	2025	Tuberk Toraks	§3.1
41544643	SACHI	2026	Lancet	§2.2, §3.2, §3.5

7.2 Verification

Every PMID is directly accessible via https://pubmed.ncbi.nlm.nih.gov/{PMID}/
Every NCT id via https://clinicaltrials.gov/study/{NCT_id}/
If you find a discrepancy between a PMID in this report and its PubMed entry (trial name / year / conclusion), please flag it for correction.

Closing

NSCLC over the past 25 years has been oncology’s most rapidly changing field — from four-way-tied chemo doublets in 2002 to 10 drivers × 3 IO strategies × the perioperative matrix in 2026, decision-making complexity has grown exponentially.

The flip side of complexity is precision. The “possible median OS” a newly diagnosed stage IV NSCLC patient can now expect has moved from ~8 months in 2002 to ~47 months in EGFRm (FLAURA2 final OS), ~12 months + ADC in HER2 ex20, ~34 months + repotrectinib in ROS1, and 30% more cure in resectable disease via perioperative therapy.

This report’s value is not in exhaustively listing every trial (PubMed does that) but in compressing 25 years of evolution + current decisions + unsolved gaps into the cognitive bandwidth of a single read. The next time you face a newly diagnosed NSCLC patient, every branch of the decision tree has this map to consult, trace, and question.

Clinician × AI = Research Superpower + Clinical Decision Amplifier

—— Dual Brain Lab · 2026-04-17